Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin

Diagnostic Microbiology and Infectious Disease

Volumn 36, Issue 4, 2000, Pages 261-268

  Wong, Samson Sai Yin ^a   Ng, Tak Keung ^b   Yam, Wing Cheong ^a   Tsang, Dominic Ngai Chong ^c   Woo, Patrick Chiu Yat ^a   Fung, Samuel Ka Shun ^b   Yuen, Kwok Yung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFOPERAZONE; CEFPIROME; CEFPODOXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; FUSIDIC ACID; IMIPENEM; NETILMICIN; RIFAMPICIN; SULPERAZON; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS;

AGED; AMPICILLIN; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CARRIER PROTEINS; DNA, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FATAL OUTCOME; FEMALE; HEXOSYLTRANSFERASES; HUMANS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON; MIDDLE AGED; MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE; PENICILLIN-BINDING PROTEINS; PENICILLINS; PEPTIDYL TRANSFERASES; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0034074492     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00141-8     Document Type: Article

References (22)

1. Barr J.G., Smyth E.T., Hogg G.M. In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis. 9:1990;804-809.
2. Update Staphylococcus aureus with reduced susceptibility to vancomycin - United States . MMWR Mor Mortal Wkly Rep. 46:1997;813-815.
3. Chambers H.F. Methicillin resistance in staphylococci molecular and biochemical basis and clinical implications . Clin Microbiol Rev. 10:1997;781-791.
4. Climo M.W., Patron R.L., Archer G.L. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother. 43:1999;1747-1753.
5. de Neeling A.J., van Leeuwen W.J., Schouls L.M., Schot C.S., van Veen-Rutgers A., Beunders A.J., Buiting A.G.M., Hol C., Ligtvoet E.E.J., Petit P.L., Sabbe L.J.M., van Griethuysen A.J.A., van Embden J.D.A. Resistance of staphylococci in The Netherlands surveillance by an electronic network during 1989-1995 . J Antimicrob Chemother. 41:1998;93-101.
6. Eliopoulos, G. M. & Moellering Jr R. C. (1996). Antimicrobial combinations. In: V. Lorian (Ed.), Antibiotics in Laboratory Medicine (pp. 330-396). Baltimore, MD: Williams and Wilkins.
7. Geisel R., Schmitz F.I., Thomas L., Berns G., Zetsche O., Ulrich B., Fluit A.C., Labischinsky H., Witte W. Emergence of heterogenous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area. J Antimicrob Chemother. 43:1999;846-848.
8. Hiramatsu K., Aritaka N., Hanaki H., Kawasaki S., Hosoda Y., Hori S., Fukuchi Y., Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogenously resistant to vancomycin. Lancet. 350:1997;1670-1673.
9. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
10. King T.C., Schlessinger D., Krogstad D.J. The assessment of antimicrobial combinations. Rev Infect Dis. 3:1981;627-633.
11. Kloos W.E., Bannerman T.L. Staphylococcus and Micrococcus. Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., Yolken R.H. Manual of Clinical Microbiology. 1995;282-298 American Society for Microbiology, Washington DC.
12. Maki D.G., Weise C.E., Sarafin H.W. A semiquantitative culture method for identifying intravenous-catheter-related infection. N Eng J Med. 296:1977;1305-1309.
13. Moreira B., Boyle-Vavra S., de Jonge B.L.M., Daum R.S. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. J Clin Microbiol. 41:1997;1788-1793.
14. Performance standards for antimicrobial disk susceptibility tests. Approved standards M2-A6. 1997;NCCLS, Villanova, PA.
15. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standards M7-A4. 1997;NCCLS, Villanova, PA.
16. Performance standards for antimicrobial susceptibility testing; ninth informational supplement M100-S9. 1999;NCCLS, Villanova, PA.
17. Ploy M.C., Grélaud C., Martin C., de Lumley L., Dennis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 351:1998;1212.
18. Seibert G., Isert D., Klesel N., Limbert M., Markus A., Schrinner E. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. J Antimicrob Chemother. 29:(suppl A):1992;25-30.
19. Sieradzki K., Roberts R.B., Haber S.W., Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Eng J Med. 340:1999;517-523.
20. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B., Tenover F.C., Zervos M.J., Band J.D., White E., Jarvis W.R. Emergence of vancomycin resistance in Staphylococcus aureus. N Eng J Med. 340:1999;493-501.
21. Tenover F.C., Lancaster M.V., Hill B.C., Steward C.D., Stocker S.A., Hancock G.A., O'Hara C.M., McAllister S.K., Clark N.C., Hiramatsu K. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol. 36:1998;1020-1027.
22. Wong S.S.Y., Ho P.L., Woo P.C.Y., Yuen K.Y. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis. 29:1999;760-767.